NYSE:ZOMZomedica Pharmaceuticals Corp (NYSEAMERICAN) Stock Price, Forecast & News

$0.21

-0.01 (-3.68 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.20

Now: $0.21▼

$0.22

50-Day Range

$0.13

MA: $0.18▼

$0.27

52-Week Range

$0.11

Now: $0.21▼

$0.50

Volume14.61 million shs

Average Volume16.91 million shs

Market Capitalization$23.21 million

P/E RatioN/A

Dividend YieldN/A

Beta0.09

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

2.2 Community Rank

Outperform Votes
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has received 147 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has received 194 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has received 56.89% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and other stocks. Vote “Outperform” if you believe ZOM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) does not currently pay a dividend.
Dividend Growth
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zomedica Pharmaceuticals Corp (NYSEAMERICAN) insiders have not sold or bought any company stock.
Percentage Held by Insiders
51.80% of the stock of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.87% of the stock of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) are expected to grow in the coming year, from ($0.07) to ($0.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

0.77 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:ZOM

Previous Symbol

CUSIPN/A

CIK1684144

Webwww.zomedica.com

Phone734-369-2555

Debt

Debt-to-Equity RatioN/A

Current Ratio1.20

Quick Ratio1.20

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.09) per share

Price / Book-2.39

Profitability

EPS (Most Recent Fiscal Year)($0.19)

Net Income$-19,780,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-166.87%

Miscellaneous

EmployeesN/A

Outstanding Shares108,038,000

Market Cap$23.21 million

Next Earnings Date8/13/2020 (Estimated)

OptionableNot Optionable

Receive ZOM News and Ratings via Email

Sign-up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Frequently Asked Questions

How has Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock been impacted by COVID-19 (Coronavirus)?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock was trading at $0.2078 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZOM shares have increased by 3.4% and is now trading at $0.2148. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

When is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s next earnings date?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

How were Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings last quarter?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) released its quarterly earnings results on Wednesday, February, 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.01. View Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings history.

Has Zomedica Pharmaceuticals Corp (NYSEAMERICAN) been receiving favorable news coverage?

Press coverage about ZOM stock has trended very positive on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) earned a news impact score of 4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutZomedica Pharmaceuticals Corp (NYSEAMERICAN).

Who are some of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key competitors?

Some companies that are related to Zomedica Pharmaceuticals Corp (NYSEAMERICAN) include Aptorum Group (APM), Catalyst Biosciences (CBIO), Bellerophon Therapeutics (BLPH), TFF Pharmaceuticals (TFFP), CannTrust (CTST), Genprex (GNPX), Sesen Bio (SESN), Clearside Biomedical (CLSD), Celsion (CLSN), Proteostasis Therapeutics (PTI), ContraFect (CFRX), Milestone Pharmaceuticals (MIST), Monopar Therapeutics (MNPR), Adamas Pharmaceuticals (ADMS) and SCYNEXIS (SCYX). View all competitors.

What other stocks do shareholders of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals Corp (NYSEAMERICAN) investors own include Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Acasti Pharma (ACST), Amarin (AMRN), Anavex Life Sciences (AVXL), Clearside Biomedical (CLSD), Allena Pharmaceuticals (ALNA) and Aileron Therapeutics (ALRN).

Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key executives?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s management team includes the following people:

Mr. Gerald L. Solensky Jr., Chairman, CEO & Pres (Age 44)
Dr. Stephanie Morley DVM, COO & VP of Product Devel. (Age 43)
Mr. Robert W. DiMarzo, Exec. VP of Global Strategy (Age 61)
Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 51)
Mr. Bruk Herbst, Chief Commercial Officer (Age 49)

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock symbol?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZOM."

Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s major shareholders?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock is owned by a number of retail and institutional investors. Top institutional investors include Cambridge Investment Research Advisors Inc. (11.34%). Company insiders that own Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock include James Lebar and Rodney James Williams. View institutional ownership trends for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

Which institutional investors are buying Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock?

ZOM stock was bought by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc.. View insider buying and selling activity for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

How do I buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Shares of ZOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock price today?

One share of ZOM stock can currently be purchased for approximately $0.21.

How big of a company is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a market capitalization of $23.21 million. The company earns $-19,780,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.

What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s official website?

The official website for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is www.zomedica.com.

How can I contact Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?

Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s mailing address is 100 PHOENIX DRIVE SUITE 190, ANN ARBOR MI, 48108. The company can be reached via phone at 734-369-2555 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff